ArticleJournal of clinical microbiology2009
Spectrum of zygomycete species identified in clinically significant specimens in the United States.
Article in Journal of clinical microbiology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 76 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed.
- Challenges in ITS-based identification ofMicrobiology spectrum · 2026Article
- The molecular basis of intrinsic resistance to azoles inAntimicrobial agents and chemotherapy · 2026Article
- Two decades of mucormycosis: molecular epidemiology and antifungal susceptibility trends in Türkiye.Frontiers in cellular and infection microbiology · 2026Article
- Chronic cutaneous and mucosal mucormycosis:Emerging microbes & infections · 2025Article
- Gastrointestinal mucormycosis byMedical mycology case reports · 2025Article
- Epidemiology, pathogenesis, clinical characteristics, and treatment of mucormycosis: a review.Annals of medicine · 2024Review
- Rediscovering the chemistry of theRSC advances · 2024Review
- A Study on the Involvement of Facial Bones in Mucormycosis Patients.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2024Article
- RecurrentMedical mycology case reports · 2024Article
- Antibacterial and Antifungal Potential ofAntibiotics (Basel, Switzerland) · 2024Review
- Symmetric and asymmetric DNA N6-adenine methylation regulates different biological responses in Mucorales.Nature communications · 2024Article
- The First Case of Pulmonary Mucormycosis Caused byAnnals of laboratory medicine · 2024Article
- Peritoneal dialysis-associated peritonitis from pauci-septated mold: Life-threatening but curable.Medical mycology case reports · 2023Article
- The application of metagenomic next-generation sequencing in patients with infection or colonization caused byFrontiers in cellular and infection microbiology · 2023Article
- New Perspectives on Antimicrobial Agents: Isavuconazole.Antimicrobial agents and chemotherapy · 2022Review
- Development of a Monoclonal Antibody and a Serodiagnostic Lateral-Flow Device Specific toJournal of fungi (Basel, Switzerland) · 2022Article
- Mucormycosis: risk factors, diagnosis, treatments, and challenges during COVID-19 pandemic.Folia microbiologica · 2022Review
- Genetic Manipulation in Mucorales and New Developments to Study Mucormycosis.International journal of molecular sciences · 2022Review
- In vitro Activity of Isavuconazole and Comparators Against Clinical Isolates of Molds from a Multicenter Study in China.Infection and drug resistance · 2022Article
- Mucormycosis co-infection in COVID-19 patients: An update.Open life sciences · 2022Review
16 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several members of the order Mucorales (subphylum Mucoromycotina) are important agents of severe human infections. The identification of these fungi by using standard mycologic methods is often difficult and time consuming. Frequently, the etiological agent in clinical cases is reported either as a Mucor sp., which is not the most frequent genus of zygomycetes, or only as a member of the Mucorales. For this reason, the actual spectrum of species of zygomycetes and their incidences in the clinical setting is not well known. The goals of this study were to compare the results of the molecular identification of an important set of clinical isolates, received in a mycological reference center from different regions of the United States, with those obtained by using the traditional morphological methods and to determine the spectrum of species involved. We tested 190 isolates morphologically identified as zygomycetes by using sequencing of the internal transcribed spacer (ITS) region of the ribosomal DNA. Molecular identification revealed that Rhizopus oryzae represented approximately half (44.7%) of these isolates. The remainder was identified as Rhizopus microsporus (22.1%), Mucor circinelloides (9.5%), Mycocladus corymbifer (formerly Absidia corymbifera) (5.3%), Rhizomucor pusillus (3.7%), Cunninghamella bertholletiae (3.2%), Mucor indicus (2.6%), Cunninghamella echinulata (1%), and Apophysomyces elegans (0.5%). The most common anatomic sites for clinically significant zygomycetes, as determined by isolates sent to the Fungus Testing Laboratory for identification and/or susceptibility testing and included in this study, were the sinuses, lungs, and various cutaneous locations, at 25.8%, 26.8%, and 28%, respectively. These sites represented approximately 80% of the isolates evaluated. A high level of correlation (92.6%) between morphological and molecular identifications was found.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.